The high cost of cancer drugs makes it difficult for public and private health care systems to provide patients with up-to-date treatment. If this trend continues, it will be increasingly difficult forRead More…
According to the World Health Organization (WHO), cancer is the second leading cause of death in the world. In 2018 alone, 9.6 million people worldwide died of cancer, accounting for about 1/6Read More…
B lymphocytes can only produce a proprietary antibody against an antigen determinant, so it has the characteristics of highly specific physical and chemical properties, single biological activity, strong binding specificity with antigenRead More…
The Antibodies are secreted by plasma cells transformed from B cells, and each B cell line can produce only one specific antigenic determinant. The antibody, produced from a single cell line, isRead More…
The outbreak of Ebola in 2014 in West Africa killed more than 11000 people. At the time, scientists were working on several experimental vaccines and treatments, but none of them were approvedRead More…
Most CAR-T cell therapies require targeting cancer cell-specific antigens. Now, there is a new way to target the environment around the tumor, which comes from nanobodies naturally produced by free alpacas, camelsRead More…
Melanin protects us from the sun’s destructive rays by absorbing light energy and converting it into heat. A recent study has shown that this can make it a very effective tool forRead More…
Scientists, from the German Cancer Research Center (DKFZ), have successfully reconstructed biomolecules in the form of images. The goal of the researchers is to create a mirror artificial protein synthesis system. InRead More…
Alzheimer’s disease (AD) is a neurodegenerative disease common in the elderly. The main pathological changes were diffuse atrophy of cerebral cortex, neurofibrillary tangles and the formation of a large number of senileRead More…
Swiss pharmaceutical giant Roche recently announced that the Food and Drug Administration (FDA) has accepted the biologics licensing application (BLA) of polatuzumab vedotin, antibody drug conjugate (ADC), and granted priority review. TheRead More…